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Background:  Many  of  the  world’s  vaccine  supply  chains  do  not  adequately  provide  vaccines,  promp-
ting  several  questions:  how  are  vaccine  supply  chains  currently  structured,  are  these  structures  closely
tailored  to individual  countries,  and  should  these  supply  chains  be  radically  redesigned?
Methods:  We  segmented  the  57  GAVI-eligible  countries’  vaccine  supply  chains  based  on  their
structure/morphology,  analyzed  whether  these  segments  correlated  with  differences  in country  char-
acteristics,  and  then  utilized  HERMES  to develop  a detailed  simulation  model  of  three  sample  countries’
supply  chains  and  explore  the cost  and  impact  of various  alternative  structures.
Results:  The  majority  of  supply  chains  (34  of  57) consist  of four  levels,  despite  serving  a wide  diversity  of
geographical  areas  and  population  sizes.  These  four-level  supply  chains  loosely  fall  into  three  clusters  [(1)
18 countries  relatively  more  bottom-heavy,  i.e., many  more  storage  locations  lower  in the  supply  chain,
(2) seven  with  relatively  more  storage  locations  in  both  top  and  lower  levels,  and (3)  nine  comparatively
more  top-heavy]  which  do not correlate  closely  with  any  of  the  country  characteristics  considered.  For
all  three  cluster  types,  our  HERMES  modeling  found  that simpliﬁed  systems  (a central  location  shipping
directly  to  immunization  locations  with  a  limited  number  of Hubs  in between)  resulted  in lower  operating
costs.
Conclusion:  A  standard  four-tier  design  template  may  have  been  followed  for  most  countries  and  raises
the possibility  that  simpler  and  more  tailored  designs  may  be warranted.. Introduction
Many countries across the world may  be outgrowing their cur-
ent vaccine distribution systems [1–6]. Designed in the 1970s,
hese vaccine supply chains (i.e., the series of steps, processes, loca-
ions, vehicles, and personnel involved in getting vaccines from
nitial delivery into a country all the way to the people) have long
∗ Corresponding author at: Department of International Health, International Vac-
ine Access Center (IVAC), Global Obesity Prevention Center (GOPC), Johns Hopkins
loomberg School of Public Health, 855N. Wolfe St., Suite 600, Baltimore, MD 21205,
nited States. Tel.: +1 443 287 6705; fax: +1 443 287 6714.
E-mail address: brucelee@jhu.edu (B.Y. Lee).
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provided life-improving and life-saving vaccines to the world’s
populations, thus preventing countless disease cases and deaths
and saving health care costs and productivity losses [7–16]. How-
ever, all innovations eventually require updating. Are the same
supply chain designs applicable today or are they outdated with
continuing population growth, expanded target populations, and
new vaccine introductions (NVIs) to different countries’ World
Health Organization (WHO) Expanded Program on Immunization
(EPI) schedules? Indeed, evidence suggests that supply chain lim-
itations are preventing many mothers and children from getting
vaccinated [17–21]. This situation could grow worse throughout
this decade, dubbed the “Decade of Vaccines” by Bill and Melinda
Gates for an unprecedented number of planned NVIs which have led
to development of the Global Vaccine Action Plan (GVAP). Delivery
problems also waste signiﬁcant resources that have been invested
in developing and manufacturing vaccines.
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Tackling whether and how to redesign vaccine supply chains
equires an understanding of their current structures. Therefore,
e ﬁrst performed a segmentation analysis of the 57 GAVI-eligible
ountries’ vaccine supply chains, proﬁling and dividing them into
ogical groups to establish a general taxonomy of GAVI-eligible
ountry vaccine supply chains (Appendix A). We  investigated
ow the observed supply chain morphologies correlate with the
ountries’ characteristics to establish whether there is a rationale
or the current supply chain designs. After this segmentation anal-
sis, we chose three sample countries’ vaccine supply chains from
he largest segment and utilized mathematical and computational
odeling to explore how structures and operations could improve
hrough radical redesign (i.e., substantially simplifying the supply
hain structure by eliminating all intermediate storage locations
xcept those identiﬁed as necessary from a cost standpoint).
. Methods
.1. GAVI-eligible countries
The GAVI Alliance is a public–private global health partner-
hip that aims to increase access to vaccines for the world’s
owest-income countries. At the time of this study, a country was
onsidered GAVI-eligible if its Gross National Income (GNI) per
apita was below or equal to US $1520 [22–24]. Table 1 lists the
7 GAVI-eligible countries and some of their relevant characteris-
ics. We  focused on these countries due to their established need
or assistance in improving childhood immunization coverage. Our
oal was to explore whether these countries simply require sup-
ort for purchasing vaccines or their immunization systems need
mprovement.
.2. Segmenting GAVI-eligible country supply chains by their
tructure and morphology
We  compiled data on each GAVI country and its vaccine supply
hain (Appendix A) and segmented the supply chains into clusters
ased on their structures, characteristics, and morphologies. The
rst segmentation variable was the number of supply chain lev-
ls (i.e., the number of storage locations a vaccine traverses before
eing administered).
The second segmentation variable was supply chain morphol-
gy, determined by calculating the average “branching ratio” for
ach level. The average branching ratio for a level is the number of
ocations in the next lower level divided by the number of locations
n the current level (e.g., a District level has a branching ratio of ten
f, on average, each Store serves ten immunization locations). Cal-
ulating branching ratios helped determine how “top-heavy” (i.e.,
igher branching ratios in the higher levels) or “bottom-heavy” (i.e.,
igher branching ratios in the lower levels) each supply chain is.
We used Stata, Version 11.2 (Stata Corporation, College Station,
exas) to determine the correlations between various country
haracteristics (i.e., gross domestic product per capita, under-ﬁve
ortality, average life expectancy, total land size, expected 2015
urviving birth cohort), average catchment area (i.e., the geographic
rea divided by the number of immunization locations), aver-
ge catchment population (i.e., the expected 2015 surviving birth
ohort divided by the number of immunization locations), and
umber of non-immunization supply chain locations (i.e., storage
nd distribution locations). Because detailed data were available for
nly a subset of countries’ EPI programs, we based cross-country
omparisons on the average catchment area and population. It is
nlikely that the actual distributions of catchment areas and popu-
ations would correlate differently with the supply chain structures. (2015) 4451–4458
2.3. Modeling to identify and evaluate potential simpliﬁed
redesigns of the vaccine supply chain
From the resulting largest GAVI country vaccine supply chain
segment, we  selected three sample countries to further explore
how they could be redesigned and improved. We  utilized the HER-
MES modeling software (Appendix B), developed by our HERMES
Logistics Modeling Team, to generate detailed discrete-event simu-
lation models for each country, which served as virtual laboratories
for evaluating the current structures and alternative designs using
the following steps [17–21]:
• Simulate the supply chain for 2015: This involved extrapolating
the country’s population (based on its expected GAVI cohort) to
match projected 2015 population numbers and adding sched-
uled NVIs to the system. The simulation was  run over one virtual
year and helped identify future constraints and bottlenecks if no
redesign or improvements occur.
• Perform a “gap analysis”: This analysis determined the additional
storage and transport requirements necessary to fulﬁll demand
100% at all immunization locations without changing the fre-
quency or mode of delivery (i.e., what needs to be added to
alleviate bottlenecks).
• Simulate the supply chain for 2015 after relieving bottlenecks by
adding capacity based on the gap analysis: After the “gap analysis”
identiﬁed the additional capacity needed, we added the necessary
storage devices and transport vehicles to the system (taking into
account planned new vaccine introductions), re-ran the simula-
tions, and then tabulated the required capital expenditures and
resulting operational costs.
• Identify an optimized structure for the supply chain: Our team
created a network design optimization model (Appendix B) to
identify alternative simpliﬁed designs for the vaccine supply
chain.
• Perform a “gap analysis” on the simpliﬁed/optimized supply
chain for 2015
• Simulate the simpliﬁed supply chain for 2015 after relieving bot-
tlenecks by adding capacity based on the gap analysis: Once the
bottlenecks were alleviated, we  performed the simulations for
the simpliﬁed system, tabulating the capital expenditures needed
to achieve the system and resulting operating costs. Note that
these capital expenditures assume the purchase of new equip-
ment (storage and transport) rather than repurposing of existing
equipment from current locations and transport routes which no
longer exist in the simpliﬁed system.
3. Results
3.1. The structures of GAVI-eligible country vaccine supply chains
As Fig. 1 shows, the number of supply chain levels ranges from
three to ﬁve. Fig. 2 uses box plots to compare the distribution of
some key GAVI country characteristics for the three-level, four-
level, and ﬁve-level segments. While three-level vaccine supply
chain countries tend to be amongst the smallest in both land and
population size and ﬁve-level countries tend to be amongst the
largest, there is considerable overlap. There is also overlap among
the three segments in other characteristics such as gross domes-
tic product per capita, average immunization location catchment
area and population, under-ﬁve mortality, life expectancy, and the
Logistics Performance Index (LPI). Measured by the World Bank,
the LPI scores factors affecting supply chain logistics in a country,
such as the quality of infrastructure.
We further examined the 34 four-level country supply chains
(Fig. 3). (Yemen was  excluded due to incomplete data.) To study the
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Table  1
GAVI-eligible countries’ characteristics and new vaccine introduction schedule.
Country name 2011
Populationa
(in millions)
2015 Birth
cohortb
(in millions)
Country areac
(million km2)
No. of
levels
2010 GDPd
per capita
(GKD)
2010 Life
expf at
birth, total
Selected planned new vaccine
introductions and year
MenA Hib Rota virus PCV
Afghanistan 30.1 1.32 0.65 5 1207 48.3 2013 2012
Bangladesh 166.6 3.09 0.13 3 1659 68.6 2012 2014
Benin 9.5 0.34 0.11 4 1587 55.6 2012 2012 2010
Burkina Faso 16.8 0.68 0.27 4 1256 54.9 2010 2016 2011
Burundi 8.7 0.28 0.03 3 409 49.9 2016 2012 2010
Cambodia 15.3 0.29 0.18 4 2194 62.5 2010 2015 2012
Cameroon 20.4 0.69 0.47 4 2294 51.1 2011 2012 2010
Central African Republic 4.6 0.14 0.62 4 789 47.6 2015 2016 2012
Chad  11.8 0.51 1.2 4 1370 49.2 2011 2018 2014
Comoros 0.71 0.03 0.002 4 1096 60.6 2018 2016
Congo, Dem Republic of 69.7 2.82 2.27 5 347 48.1 2014 2013 2011
Côte  d’Ivoire 22.1 0.64 0.32 4 1899 54.7 2014 2016 2012
Djibouti 0.89 0.02 3 2308e 57.5 2012 2011
Eritrea 5.4 0.20 0.10 3 546 61.0 2016 2015 2013
Ethiopia 87.2 2.49 1.00 4 1041 58.7 2013 2012 2010
Gambia 1.8 0.06 0.01 3 1410 58.2 2013 2011
Ghana 24.8 0.76 0.23 5 1644 63.8 2012 2011 2011
Guinea 10.6 0.39 0.25 4 1091 53.6 2014 2014 2012
Guinea Bissau 1.7 0.03 3 1186 47.7 2016 2012 2011
Haiti  10.3 0.27 0.03 3 1111 61.8 2011 2020 2019
India  1230.7 2.97 5 3425 65.1 2011 2015 2014
Kenya 41.9 1.53 0.57 4 1651 56.5 2015 2011 2010
Korea, DPR 24.1 0.32 0.12 4 N/A 68.5 2011 2020 2019
Kyrgyz Republic 5.6 0.13 0.19 4 2239 69.4 2012 2018
Lao  PDR 6.5 0.14 0.23 4 2551 67.1 2015 2013
Lesotho 2.1 0.03 3 1601 47.4 2014 2012
Liberia 4.2 0.14 0.10 3 419 56.2 2016 2012
Madagascar 20.7 0.74 0.58 4 969 66.5 2013 2011
Malawi 16.1 0.63 0.09 4 882 53.5 2012 2010
Mali  13.6 0.68 1.22 4 1065 51.0 2010 2012 2010
Mauritania 3.4 0.10 1.03 4 2456 58.2 2015 2018 2014
Mozambique 23.9 0.86 0.79 4 942 49.7 2015 2013
Myanmar 51.0 0.78 0.65 4 1950 64.7 2010 2013 2019
Nepal 30.4 0.73 0.14 4 1199 68.4 2014 2012
Nicaragua 5.9 0.12 4 2913 73.7 2010
Niger  16.5 0.77 1.27 4 728 54.3 2010 2018 2014
Nigeria 161.8 5.91 0.91 5 2399 51.4 2011 2010 2016 2011
Pakistan 188.8 4.50 0.77 4 2688 65.2 2014 2011
Papua New Guinea 7.0 0.20 0.45 4 2472 62.4 2015 2012
Rwanda 10.6 0.02 3 1163 55.1 2016 2012
São  Tomé e Príncipe 0.17 0.001 3 1899 64.3 2015 2011
Senegal 13.2 0.43 0.19 4 1935 59.0 2012 2012 2010
Sierra Leone 6.0 0.07 3 827 47.4 2015 2010
Solomon Islands 0.55 0.03 3 2710 67.5 2014 2012
Somalia 9.6 0.38 0.63 4 N/A 50.9 2020 2019
Republic of Sudan 44.1 0.97 1.86 4 2256 61.1 2012 2012 2010
South  Sudan N/A 0.64 4 N/A 61.5 2013
Tajikistan 7.2 0.19 0.14 4 2163 67.3 2012 2018
Tanzania 46.4 1.85 0.89 4 1434 57.4 2016 2011 2010
East-Timor N/A 0.01 3 928 62.0 2012 2016 2013
Togo  6.9 0.19 0.05 4 998 56.6 2014 2015 2012
Uganda 35.0 1.51 0.20 4 1272 53.6 2015 2013 2010
Uzbekistan 28.1 0.61 0.43 4 3106 68.0 2012 2018
Viet  Nam 90.0 1.54 0.31 5 3205 74.8 2010 2015 2013
Yemen 25.0 0.53 4 2653 65.0 2010 2010
Zambia 13.6 0.54 0.74 4 1562 48.5 2012 2010
Zimbabwe 12.9 0.39 0.39 4 N/A 49.9 2015 2013
a Total population in millions, GAVI, 2011.
b Birth cohort population in millions for 2015, calculated, GAVI, 2011.
c Country land area in million square kilometers, CIA World Factbook, 2012.
d Gross Domestic Product (GDP) per capita in Geary–Khamis dollar (GKD), World Bank, 2010.
e Gross Domestic Product (GDP) per capita in Geary–Khamis dollar (GKD), World Bank, 2009.
f Life expectancy, total, World Bank, 2010.
“
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gmorphologies” of this segment, we tabulated the branching ratios
t the top level (i.e., between the ﬁrst and second levels), the mid-
le level (i.e., between the second and third levels) and the bottom
evel (i.e., between the third level and leaf node level). Morpholo-
ies range from those that are relatively bottom-heavy to thosewhich are more top-heavy, falling into three clusters (Fig. 1). The
18 countries in the ﬁrst cluster have branching ratios that tend to
increase as one moves down the supply chain. The seven countries
in the second cluster tend to have higher branching ratios at the
top and the bottom levels, but lower branching ratios in the middle
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etween the second and third levels. The nine countries in the third
luster tend to have relatively higher branching ratios at the higher
evels.
The average catchment size and catchment birth cohort popula-
ion for each immunization location are highly variable across the
AVI countries (Table 1). The only indicator that has a signiﬁcant
orrelation (p < 0.01) with catchment area or catchment population
s under-ﬁve mortality. Countries with larger catchment areas for
heir immunization locations tend to have greater under-ﬁve mor-
ality (Table 2). The number of non-immunization storage locations
n a supply chain is fairly variable across GAVI countries and sig-
iﬁcantly correlates with only the size of the country’s surviving
irth cohort. Future analyses may  assess correlations with other
ariables, such as composite EVM scores.
.2. Sample Country A
Country A has a four-level vaccine supply chain that falls into
luster 1 and in 2011, provided a vaccine availability of 90%. Our
aseline runs suggest that in 2015, with rotavirus and pneumococ-
al vaccines added to the WHO  EPI, Country A’s vaccine supply chain
ill experience transport bottlenecks between all levels (most
gregious between the District Stores and immunization locations)
nd storage bottlenecks at all levels, dropping vaccine availability
o 25% and resulting in a logistics costs per dose administered of
0.54 (Table 3).
As Table 3 shows, simply adding both transport and storage
apacity (two new large cold rooms at the Central level, four large
able 2
orrelation analysis of indicators.
Average catchment area
(km2/no. of immunization
locations)
GDP 0.083 
Under-ﬁve mortality 0.465*
Life  expectancy −0.242 
Land  size – 
GAVI  surviving birth cohort 0.078 
Catchment area – 
Catchment population – 
* Indicates signiﬁcant correlation (p < 0.01).ntry vaccine supply chains.
cold rooms and buildings to house them at the Regional level, 29
(216 L) net refrigerators at the District level, 327 (76 L) net refrig-
erators at the immunization locations, and enough cold boxes to
ﬁll the 94 new trucks) could alleviate these bottlenecks, improve
the vaccine availability to ∼100%, decrease the logistics cost per
dose administered to $0.28, and entail a total capital expenditure
of about $6.7 million USD.
As Table 3 delineates, changing the bottom level transport from
motorcycles that travel from one immunization location to one
District Store to trucks that make loops from one District Store
to four immunization locations could drop the logistics cost per
dose administered even further. We  assumed four immunization
locations per loop because this represents a workload that can be
completed in one day. The annual operating costs are higher in
this scenario, but the logistics cost per dose is lower because more
patients can be served.
The network optimization model identiﬁed two  potential struc-
tures, each with one Central Store and merging the current Regional
and District sites into (1) seven Regional Hubs, and (2) 14 Regional
Hubs. Table 3 shows the capital expenditure required to achieve
this structure and the resulting operating costs. The limitation of
the seven-Hub structure is that a number of longer trips would
result, with 15% of the routes requiring two  days. However, the
14-Hub structure would reduce the number of trips to 4% of the
routes requiring over two days and maintain the same logistics
cost per dose as the seven-Hub structure but require a higher
capital expenditure (Table 3). Note that all of these capital expendi-
tures could signiﬁcantly decrease if existing storage and transport
Average catchment population
(GAVI surviving cohort/no. of
immunization locations)
Non-immunization
sites
0.149 0.128
−0.113 −0.098
0.192 0.213
0.058 0.206
– 0.461*
– −0.145
– 0.005
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lFig. 2. Comparison of characteristics for 
quipment from current locations that would no longer be required
n a simpliﬁed system could be repurposed..3. Sample Country B
Country B also has a four-level vaccine supply chain. Our base-
ine runs suggest that in 2011, without pneumococcal vaccines, thelevel, four-level and ﬁve-level countries.
logistics cost per dose would be $0.46. If no storage or transport is
added, by 2015 (with pneumococcal vaccine added to the WHO
EPI) Country B’s vaccine supply chain will experience transport
bottlenecks at all levels, particularly at the top level where there
are currently no cold trucks, and storage bottlenecks at the Cen-
tral and Regional levels, plummeting vaccine availability to 29%.
Prior to any ﬁx, the 2015 logistics cost per dose would be $0.65
4456 B.Y. Lee et al. / Vaccine 33 (2015) 4451–4458
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Table 3). Table 3 shows how adding transport loops (i.e., 4 × 4
rucks instead of motorcycles and allowing these trucks to deliver
o four Health Centers per trip) and needed transport capacity to
his ﬁx could lead to some additional gains similar to those seen in
ountry A.
The network optimization model identiﬁed three potential sim-
liﬁed structures for Country B, each with one Central store and
erging the current Regional and functional District sites into (1)
even Regional Hubs, (2) 14 Regional Hubs and (3) 28 Regional
ubs. Table 3 shows the capital expenditures required to achieve
ach of these structures and the resulting operating costs. The lim-
tation of the seven-Hub structure is that a number of long trips
ould result; about 23% of the routes would be over 3 days. Dou-
ling the number of Hubs would decrease the number of routes over
hree days to about 11%. When 28-Hubs are used, the number of
outes exceeding three days decreases to about 5%. Again, reassign-
ng existing transport and storage equipment could substantially
educe capital expenditures.evel supply chains.
3.4. Sample Country C
Country C has a four-level vaccine supply chain that falls into
Cluster 3. Our baseline runs suggest prior to any ﬁx, the logis-
tics cost per dose at baseline in 2015 would be $1.17. Alleviating
bottlenecks to get coverage up to ∼100% would necessitate the
addition of seven cold rooms and one truck at the Central Store;
three cold rooms, four refrigerated trucks, and two  trucks at the
Regional level; 183 refrigerators (216−105 L) and ﬁve trucks at the
District level; and 909 (75–99 L) net refrigerators at the immuniza-
tion locations; entailing a total capital expenditure of $2.4 million
(Table 3). This ﬁgure is lower than all the scenarios in Countries A
and B because Country C is already using trucks and looped routes
to serve the lowest level in the supply chain. The resulting annual
logistics cost per dose administered would be $0.60 less than the
2015 baseline logistics cost per dose (Table 3).
The network optimization model identiﬁed two potential sim-
pliﬁed structures, each with one Central store and consolidating
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Regional and District stores into (1) 12 Regional Hubs and (2) 25
Regional Hubs with the required capital expenditures and result-
ing operating costs seen in Table 3. Once again, reassigning existing
transport and storage equipment could substantially reduce these
expected capital expenditures.
The drawback of the 12-Hub structure is that 30% of the trips
would be two  or more days, compared to 16% of the trips in the
25-Hub structure. Only 1% of the trips in the 25-Hub case would be
three or more days in duration.
4. Discussion
The vast majority of GAVI-eligible countries have vaccine sup-
ply chains that consist of four levels, despite their wide diversity
of geographical areas, population sizes, and other characteristics.
The only exceptions are a few particularly large countries with
ﬁve-level vaccine supply chains (India and the Democratic Peo-
ple’s Republic of the Congo, among others) and a small group of
smaller countries that have three-level supply chains (Burundi, Dji-
bouti, Gambia, São Tomé e Príncipe, and East Timor, among others).
This striking consistency among GAVI-eligible countries suggests
that a standard four-tier design template may have been followed
for most countries. When a standard format is being followed,
one must wonder whether a more tailored approach is warranted.
Indeed, our analyses of three sample countries suggest that there
may  be an excess of storage locations and transport routes in many
vaccine supply chains.
Our modeling suggests that simpliﬁed systems may  provide
substantial cost savings for countries in the largest (i.e., four-
level) GAVI vaccine supply chain segment. For two of the sample
countries, the simpliﬁed system accrued not only lower operat-
ing costs but also lower capital expenditures than maintaining the
current system structure and relieving the bottlenecks. The third
required higher capital expenditures but resulted in lower oper-
ating costs. While other countries in this four-level segment may
vary, these ﬁndings that simpliﬁed systems may be favorable are
encouraging. Future work can explore these solutions in the other
GAVI four-level (and three- and ﬁve-level) supply chain countries.
There are advantages to having more levels and storage loca-
tions in a supply chain. Adding levels essentially decentralizes
operations, spreading responsibility and risk throughout more
locations and improving response time. For example, having more
levels may  allow a supply chain to respond faster to unexpected
events because distribution centers are closer to the immunization
locations. Having more storage locations and transport routes can
reduce vulnerability to events such as power outages, ﬁre, theft,
personnel loss, and vehicle breakdowns. Having more levels also
reduces the distance each vehicle travels.
However, these advantages may  not outweigh the disadvan-
tages. Having too many levels complicates coordination, increases
the number of sites to manage, reduces economies of scale,
and introduces redundancies. Additional levels also contribute to
increased time spent in storage, raising the risk of wastage due
to temperature exposure or expiry. As a result, many commercial
supply chains opt for fewer levels (e.g., automotive distribution tra-
ditionally has three levels: the manufacturing site where cars are
built, intermediate distribution points, and dealerships, analogous
to the Central Store, Hub, and immunization locations, respectively)
[27].
In improving supply chains, operations costs may  not be the only
factor to consider. The choice of storage locations often results from
political considerations (e.g., Districts with more political clout may
have more locations or locations may  be placed in highly visible
areas for visitors). Storage locations may  also serve multiple pur-
poses (e.g., storing other medical products, food, and durable goods)
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United Kingdom: GXS Limited. Available at: http://www.edibasics.co.uk/edi-
by-industry/the-automotive-industry/.[Accessed 18 June, 2012].
[28] GAVI Alliance. GAVI strategy: phase IV (2016–20). Geneva, Switzerland: GAVI
Alliance; 2015. Available at: 〈http://www.gavi.org/About/Strategy/Phase-IV-458 B.Y. Lee et al. / Vacc
nd gainfully employ people who may  otherwise be unemployed.
ccess to skilled labor, local weather, and road conditions may  also
lay key roles.
Additionally, various redesign options may  be more or less desir-
ble depending on funding sources. For example, a stakeholder who
s responsible for funding capital costs but not operating costs may
refer system changes that incur lower capital expenditures rather
han selecting a design with lower operating costs. Or if a country
as recently invested in expanding cold chain capacity, stakehol-
ers may  not prioritize redesign until the new equipment is nearing
he end of its useful lifetime. Preparing a redesign plan for a coun-
ry and generating buy-in may  also require substantial time and
nancial investments.
The potential solutions we suggest for these sample countries
re approximate rather than precise. The best system for every
ountry may  not be a seven-Hub or 14-Hub system, but could actu-
lly be a 10-Hub, 12-Hub, etc. system. For example, population
ensity inﬂuences the number of optimal Hubs, as more densely
opulated areas required more Hubs in the sample countries.
ountries may  also differ in the number of locations that can be
isited in a single day, as our assumption of four may  not be fea-
ible where locations are separated by long distances or difﬁcult
errain.
This analysis arose when the GAVI supply chain strategy was
eing formulated and helped provide information to the Bill and
elinda Gates Foundation (BMGF), UNICEF, WHO, and GAVI. This
tudy intends to serve as an initial exploration to further the dis-
ussion on whether vaccine supply chains ought to be simpliﬁed in
rder to meet the GAVI Supply Chain Strategy goal of strengthening
ealth systems to improve effectiveness and efﬁciency in vaccine
upply chains [28]. Subsequent work can incorporate more data
nd information from countries to move toward more precise and
mplementable solutions.
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